People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

HUNTINGTON — GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza and Wegovy started as a way to treat diabetes but have since become popular tools for weight loss. Dr. Matthew Christiansen ...

The Pharmaceuticals division grew revenues by ~4%, to ~$50.3bn, while the diagnostics division's revenues fell by ~1% ... to semaglutide, tirzepatide, and a host of other clinical stage GLP ...

Chetty, from the Yale University School of Medicine in New Haven, Connecticut, and colleagues examined advertising practices of websites selling compounded GLP-1 RAs, including semaglutide ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Just over ...

"It is estimated that by 2030, 30 million GLP-1 ... 4 (range 37-77), and 56% were women. All patients were initially seen in a community setting. Of the seven with NAION, four were taking ...

As of Jan. 29, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.

On the Big Pharma front, Hims & Hers appears to be going head-to-head with makers of weight loss drugs like Novo Nordisk’s semaglutide ... events linked to GLP-1 drugs. Among the ad’s ...

Jake Paul and Logan Paul announce boxing showdown, is it real? When (And Why) Did Ford Stop Making Tractors? Trump fires senior labor board official in ‘unprecedented and illegal’ move ...